http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-058329-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4eb6dbca25e5f9459a6c5f592728c787 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 |
| filingDate | 2006-12-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2008-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-058329-A1 |
| titleOfInvention | DERIVATIVES OF PIRAZOLO (4,3-C) PIRIDINA ACTIVE SUBSTITUTES AS QUINASE INHIBITORS, A METHOD FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITION |
| abstract | Substituted pyrazolo [4,3-c] pyridine derivatives of formula (1) and pharmaceutically acceptable salts thereof, as defined herein, process for their preparation and pharmaceutical compositions comprising them are disclosed; The compounds herein may be useful in therapy in the treatment of diseases associated with a deregulated protein kinase activity, such as cancer. Claim 1: A compound characterized in that it has the formula (1) wherein R is a straight or branched C1-6 alkyl optionally further substituted, C3-6 cycloalkyl, hetero-cycloalkyl or aryl; R1 is selected from H, halogen, nitro, NHCOR4, NHSO2R10, NR5R6, OR7, R8R9N-C1-6 alkyl, R7O-C1-6 alkyl and an optionally substituted straight or branched C1-6 alkyl, wherein: R4 is selected from H, optionally substituted or directly substituted C1-6 alkyl, C3-6 cycloalkyl, heterocycloalkyl, aryl, NR8R9, R8R9N-C1-6 alkyl and R7O-C1-6 alkyl; R5 and R6, which are the same or different, are independently selected from H, optionally substituted straight or branched C1-6 alkyl, C3-6 cycloalkyl, heterocycloalkyl, aryl, R8R9N-C2-6 alkyl and R7O-C2-6 alkyl; R7 is selected from H, optionally substituted straight or branched C1-6 alkyl, C3-6 cycloalkyl, heterocycloalkyl, aryl, and R8R9N-C2-6 alkyl; R8 and R9, which are the same or different, are independently selected from H, optionally substituted straight or branched C1-6 alkyl, C3-6 cycloalkyl, heterocycloalkyl and aryl, and R8 and R9, taken together with the N atom to which are bound, form an optionally substituted heterocycloalkyl group; R10 is optionally substituted or directly substituted C1-6 alkyl, C3-6 cycloalkyl, heterocycloalkyl or aryl; A, B, D and E represent an atom of N, CH, CR2 or CR3, and a maximum of two of A, B, D and E represent an atom of N, CR2 or CR3, where: R2 and R3 are independently selected between halogen, trifluoromethyl, nitro, OR7, NR8R9, straight or branched C1-6 alkyl optionally further substituted, R8R9N-C1-6 alkyl and R7O-C1-6 alkyl, where R7, R8 and R9 are as defined above; Ra and Rb are independently H or methyl, with the proviso that when Ra, Rb and R1 are atoms of H, then at least one of A, B, D and E is N; or isomers, tautomers, carriers, metabolites, prodrugs or pharmaceutically acceptable salts thereof. |
| priorityDate | 2005-12-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 32.